{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:07:17Z","timestamp":1793419637440,"version":"4.5.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Kratom products, which are sold legally in most of the US, contain alkaloids with opioidergic, adrenergic, and serotonergic activity. Millions of people use kratom to relieve pain, improve mood, or self-manage substance use disorders (SUDs). Kratom use has primarily been examined via surveys, in which recall biases among satisfied users may lead to minimization of transient negative outcomes. Further prospective study of kratom use, such as with ecological momentary assessment (EMA), is needed.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To characterize proximal motivators, effects, and patterns of kratom use and to assess whether use frequency is associated with motivations, effects, past-year criteria for SUD for kratom (KUD), or other substance use.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n For this prospective cross-sectional study, an intensive longitudinal smartphone-based EMA in which participants\u2019 current behaviors and experiences were repeatedly sampled in real time was conducted between July 1 and October 31, 2022. Participants comprised a convenience sample of US adults who used kratom at least 3 days per week for at least 4 weeks at the time of online screening. Criteria for past-year KUD were based on the\n Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition<\/jats:italic>\n . Data analysis was performed between November 2022 and November 2023.\n <\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n The exposure was 13\u202f401 kratom-use events across 15 days.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n A baseline survey covering demographics, health, kratom attitudes and behaviors, use motivations, other substance use, and KUD was administered before EMA. Data for the following EMA entries were then collected: event-contingent entries for kratom use (product, dose, and proximal motivations), follow-up entries (short-term effects and consequences of use events), random-prompt entries (mood), beginning-of-day entries (effects of kratom on sleep), and end-of-day entries (daily subjective descriptions of kratom effects). Bayesian regression was used to estimate means and credible intervals.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n A total of 357 participants completed the EMA. Their mean (SD) age was 38.0 (11.1) years; more than half were men (198 [55.5%]). Participants reported overall motivators of use on the baseline survey that involved managing psychiatric and SUD problems, but proximal motivators evaluated during the EMA involved situation-specific needs such as increasing energy and productivity and decreasing pain. Acute effects were considered congruent with daily obligations. Use patterns, despite having some distinguishing features, were generally similar in their motivators and effects; participants used kratom predominantly during the daytime and seemed to find use frequencies that suited their needs. Higher use patterns were associated with symptoms of physical dependence (eg, withdrawal or tolerance). Co-used substances included caffeine, nicotine, vitamins, and cannabis.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n Most participants in this study reported using kratom in a seemingly nonproblematic way. When such use appeared problematic, the key element was usually that withdrawal avoidance became a proximal motivator. Longitudinal studies examining changes in kratom use patterns and effects over time are needed.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.53401","type":"journal-article","created":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T11:31:11Z","timestamp":1706268671000},"page":"e2353401","source":"Crossref","is-referenced-by-count":53,"title":["Ecological Momentary Assessment of Self-Reported Kratom Use, Effects, and Motivations Among US Adults"],"prefix":"10.1001","volume":"7","author":[{"given":"Kirsten E.","family":"Smith","sequence":"first","affiliation":[{"name":"Real-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland"},{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leigh V.","family":"Panlilio","sequence":"additional","affiliation":[{"name":"Real-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Real-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland"},{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Grundmann","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, College of Pharmacy, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly E.","family":"Dunn","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"McCurdy","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Garcia-Romeu","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Epstein","sequence":"additional","affiliation":[{"name":"Real-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,1,26]]},"reference":[{"issue":"2","key":"zoi231568r1","first-page":"48","article-title":"The marketing of self-care and alternative therapies in the US in 2019: how industry stakeholders appeal to consumers\u2019 perceptions of novel food products and additives.","volume":"15","author":"Glover","year":"2019","journal-title":"J Food Law Policy"},{"issue":"2","key":"zoi231568r2","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1007\/s40429-023-00472-9","article-title":"Receptor selectivity and therapeutic potential of kratom in substance use disorders.","volume":"10","author":"Mukhopadhyay","year":"2023","journal-title":"Curr Addict Rep"},{"issue":"1","key":"zoi231568r3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1021\/acs.jmedchem.9b01465","article-title":"Investigation of the adrenergic and opioid binding affinities, metabolic stability, plasma protein binding properties, and functional effects of selected indole-based kratom alkaloids.","volume":"63","author":"Obeng","year":"2020","journal-title":"J Med Chem"},{"issue":"3","key":"zoi231568r4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1124\/jpet.122.001192","article-title":"Interactive effects of \u00b5-opioid and adrenergic-a2 receptor agonists in rats: pharmacological investigation of the primary kratom alkaloid mitragynine and its metabolite 7-hydroxymitragynine.","volume":"383","author":"Obeng","year":"2022","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"zoi231568r5","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1021\/acschemneuro.2c00704","article-title":"Kratom alkaloids: a blueprint?","volume":"14","author":"Smith","year":"2023","journal-title":"ACS Chem Neurosci"},{"issue":"6","key":"zoi231568r6","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1111\/add.2008.103.issue-6","article-title":"Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth).","volume":"103","author":"Boyer","year":"2008","journal-title":"Addiction"},{"key":"zoi231568r7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.751656","article-title":"Kratom alkaloids: interactions with enzymes, receptors, and cellular barriers.","volume":"12","author":"Hanapi","year":"2021","journal-title":"Front Pharmacol"},{"issue":"2","key":"zoi231568r8","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s40429-023-00466-7","article-title":"Omissions, ambiguities, and underuse of causal assessment tools: a systematic review of case reports on patients who use kratom.","volume":"10","author":"Feldman","year":"2023","journal-title":"Curr Addict Rep"},{"issue":"1","key":"zoi231568r9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13011-023-00531-4","article-title":"Evaluating health information provided to kratom consumers by good manufacturing practice-qualified vendors.","volume":"18","author":"Hill","year":"2023","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"6","key":"zoi231568r10","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1080\/00952990.2022.2083967","article-title":"Kratom use as more than a \u201cself-treatment.\u201d","volume":"48","author":"Smith","year":"2022","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"2","key":"zoi231568r11","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s40429-023-00476-5","article-title":"Kratom\u2019s emergence and persistence within the US polydrug epidemic.","volume":"10","author":"Smith","year":"2023","journal-title":"Curr Addict Rep"},{"issue":"5","key":"zoi231568r12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1080\/02791072.2015.1096434","article-title":"Experiences of kratom users: a qualitative analysis.","volume":"47","author":"Swogger","year":"2015","journal-title":"J Psychoactive Drugs"},{"key":"zoi231568r13","doi-asserted-by":"publisher","DOI":"10.1037\/pha0000656","article-title":"Novel methods for the remote study of emerging substances: application to kratom.","author":"Smith","year":"2023","journal-title":"Exp Clin Psychopharmacol"},{"issue":"4","key":"zoi231568r14","doi-asserted-by":"publisher","DOI":"10.1523\/ENEURO.0205-19.2019","article-title":"Estimation for better inference in neuroscience.","volume":"6","author":"Calin-Jageman","year":"2019","journal-title":"eNeuro"},{"issue":"8","key":"zoi231568r15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v011.i08","article-title":"FlexMix: a general framework for finite mixture models and latent class regression in R.","volume":"11","author":"Leisch","year":"2004","journal-title":"J Stat Softw"},{"issue":"4","key":"zoi231568r16","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1017\/pan.2022.20","article-title":"Ordered beta regression: a parsimonious, well-fitting model for continuous data with lower and upper bounds.","volume":"31","author":"Kubinec","year":"2023","journal-title":"Polit Anal"},{"issue":"1","key":"zoi231568r17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v080.i01","article-title":"brms: An R package for bayesian multilevel models using stan.","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J Stat Softw"},{"issue":"2","key":"zoi231568r18","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1037\/0022-006X.65.2.292.a","article-title":"Remember that? a comparison of real-time versus retrospective recall of smoking lapses.","volume":"65","author":"Shiffman","year":"1997","journal-title":"J Consult Clin Psychol"},{"issue":"5","key":"zoi231568r19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1037\/a0015197","article-title":"How many cigarettes did you smoke? assessing cigarette consumption by global report, time-line follow-back, and ecological momentary assessment.","volume":"28","author":"Shiffman","year":"2009","journal-title":"Health Psychol"},{"key":"zoi231568r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2020.107849","article-title":"Kratom (Mitragyna speciosa): user demographics, use patterns, and implications for the opioid epidemic.","volume":"208","author":"Garcia-Romeu","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"zoi231568r21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.drugalcdep.2017.03.007","article-title":"Patterns of kratom use and health impact in the US\u2014results from an online survey.","volume":"176","author":"Grundmann","year":"2017","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"zoi231568r22","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/00952990.2022.2041026","article-title":"Exploring the self-reported motivations of kratom (Mitragyna speciosa Korth.) use: a cross-sectional investigation.","volume":"48","author":"Grundmann","year":"2022","journal-title":"Am J Drug Alcohol Abuse"},{"key":"zoi231568r23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1174139","article-title":"Examining the paradoxical effects of kratom: a narrative inquiry.","volume":"14","author":"Smith","year":"2023","journal-title":"Front Pharmacol"},{"issue":"6","key":"zoi231568r24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1017\/S0140525X11000057","article-title":"Drugs as instruments: a new framework for non-addictive psychoactive drug use.","volume":"34","author":"M\u00fcller","year":"2011","journal-title":"Behav Brain Sci"},{"key":"zoi231568r25","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.108879","article-title":"Therapeutic benefit with caveats? analyzing social media data to understand the complexities of kratom use.","volume":"226","author":"Smith","year":"2021","journal-title":"Drug Alcohol Depend"},{"key":"zoi231568r26","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/968786","article-title":"Following \u201cthe roots\u201d of kratom (Mitragyna speciosa): the evolution of an enhancer from a traditional use to increase work and productivity in Southeast Asia to a recreational psychoactive drug in Western countries.","volume":"2015","author":"Cinosi","year":"2015","journal-title":"Biomed Res Int"},{"issue":"2","key":"zoi231568r27","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1080\/02791072.2015.1012610","article-title":"Social functioning of kratom (Mitragyna speciosa) users in Malaysia.","volume":"47","author":"Singh","year":"2015","journal-title":"J Psychoactive Drugs"},{"issue":"1","key":"zoi231568r28","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1037\/a0021285","article-title":"Emotional experience improves with age: evidence based on over 10 years of experience sampling.","volume":"26","author":"Carstensen","year":"2011","journal-title":"Psychol Aging"},{"issue":"1","key":"zoi231568r29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1080\/00952990.2022.2160340","article-title":"Implementing an EMA burst design in community-engaged research: participant and researcher perspectives and recommendations.","volume":"49","author":"Helle","year":"2023","journal-title":"Am J Drug Alcohol Abuse"},{"key":"zoi231568r30","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2023.2223622","article-title":"Associations between kratom-related state policy environments and kratom use in a nationally representative population in the United States.","author":"Ellis","year":"2023","journal-title":"J Psychoactive Drugs"},{"key":"zoi231568r31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.drugpo.2019.05.003","article-title":"Kratom policy: the challenge of balancing therapeutic potential with public safety.","volume":"70","author":"Prozialeck","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"2","key":"zoi231568r32","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/dta.v15.2","article-title":"Drug testing for mitragynine and kratom: analytical challenges and medico-legal considerations.","volume":"15","author":"Helander","year":"2023","journal-title":"Drug Test Anal"},{"issue":"2","key":"zoi231568r33","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1007\/s40429-023-00477-4","article-title":"Forensic implications of kratom: kratom toxicity, correlation with mitragynine concentrations, and polypharmacy.","volume":"10","author":"Papsun","year":"2023","journal-title":"Curr Addict Rep"},{"issue":"1","key":"zoi231568r35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40429-023-00465-8","article-title":"A cautionary tale of herbal supplements: what we have learned from kratom.","volume":"10","author":"Weiss","year":"2023","journal-title":"Curr Addict Rep"},{"key":"zoi231568r34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2991\/978-94-6463-112-8_23","volume-title":"Proceedings of the 1st International Conference for Health Research\u2013BRIN (ICHR 2022)","author":"Purwoko","year":"2023"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2814305\/smith_2024_oi_231568_1705675051.32247.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,26]],"date-time":"2024-01-26T11:31:17Z","timestamp":1706268677000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2814305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,26]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.53401","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,26]]}}}